For instance, abundance of tumor-infiltrating lymphocytes (TILs) and absence of lymphovascular invasion were found to be useful prognostic factors for disease-free survival in patients with HR-/HER2+ breast cancer who were treated using adjuvant trastuzumab (Lee et al., 2015). The gene discussed is ERBB2; the disease is breast carcinoma.